February 2026 digest

The Ethics of Prescribing and Access in Atopic Dermatitis: Can We Separate Them?

Therapeutic innovation in atopic dermatitis (AD) has advanced rapidly. Biologics and targeted therapies have transformed the outlook for patients with severe disease. Yet a central ethical tension is emerging: what is the value of prescribing the best treatment if patients cannot access it?

This question is particularly visible in the United States, where insurance denials, prior authorizations and administrative barriers often delay or prevent access to appropriate therapies. A recent ethical discussion (DOI: 10.1016/j.jaad.2026.01.011) ask whether physicians’ duties end with prescribing or extend to the extra work required to secure treatment approval. When effective therapies exist but remain inaccessible, the boundary between prescribing and ensuring access becomes ethically blurred. Yet the time required to navigate reimbursement pathways often comes directly at the expense of clinical dialogue. When consultations are shortened by administrative workload and uncertainty about treatment approval persists, patients may feel insufficiently heard or supported. Some then turn to alternative medicine or social media communities, where simplified narratives and misinformation can flourish. In this way, the ethical dilemma of whether to invest time in obtaining reimbursement is not only administrative or economic — it directly affects the therapeutic relationship and patient trust.

Our 2023 ISAD global health analysis (DOI: 10.1111/jdv.19723) showed that AD has become a paradigm of therapeutic inequality. In low-resource settings, access to even basic care such as emollients or topical anti-inflammatory therapy may be limited. In many middle-income countries, innovative drugs are approved but not reimbursed. In high-income systems, access may exist in principle yet remain constrained by administrative complexity or insurance structure.

Some health systems demonstrate that a better alignment between medical ethics and access is possible. In countries with universal or strongly regulated coverage, such as Germany or Japan, most approved therapies are reimbursed once indicated by specialists and patient co-payments are capped according to income. This reduces uncertainty for both patients and clinicians and allows therapeutic decisions to remain primarily medical rather than administrative.

The ethical debate should therefore not focus solely on whether individual clinicians must do additional administrative work. Rather, it should prompt collective reflection on how healthcare systems, professional societies and industry can ensure that therapeutic innovation translates into real patient benefit.